US Patent

US10738311 — Therapeutic inhibition of lactate dehydrogenase and agents therefor

Method of Use · Assigned to Dicerna Pharmaceuticals Inc · Expires 2035-10-09 · 9y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds and methods that use ds RNAs, such as Dicer substrate siRNA, to reduce lactate dehydrogenase target RNA and protein levels.

USPTO Abstract

This invention relates to compounds, compositions, and methods useful for reducing lactact dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Drugs covered by this patent

nedosiran-sodium (NEDOSIRAN SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3709`	—	nedosiran-sodium
`U-3709`	—	nedosiran-sodium
`U-3709`	—	nedosiran-sodium

Patent Metadata

Patent number: US10738311
Jurisdiction: US
Classification: Method of Use
Expires: 2035-10-09
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Dicerna Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.